1	(	_	-LRB-	-LRB-	_	11	P	_	_
2	@	_	RB	RB	_	11	VMOD	_	_
3	entity0	_	CD	CD	_	2	AMOD	_	_
4	)	_	-RRB-	-RRB-	_	2	P	_	_
5	--	_	:	:	_	11	P	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	@	_	JJ	JJ	_	8	NMOD	_	_
8	entity1	_	CD	CD	_	11	SUB	_	_
9	on	_	IN	IN	_	11	VMOD	_	_
10	friday	_	NNP	NNP	_	9	PMOD	_	_
11	approved	_	VBD	VBD	_	0	ROOT	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	first	_	JJ	JJ	_	11	OBJ	_	_
14	of	_	IN	IN	_	13	NMOD	_	_
15	a	_	DT	DT	_	17	NMOD	_	_
16	new	_	JJ	JJ	_	17	NMOD	_	_
17	class	_	NN	NN	_	14	PMOD	_	_
18	of	_	IN	IN	_	17	NMOD	_	_
19	@	_	JJ	JJ	_	21	NMOD	_	_
20	entity5	_	CD	CD	_	21	NMOD	_	_
21	drugs	_	NNS	NNS	_	18	PMOD	_	_
22	that	_	WDT	WDT	_	17	NMOD	_	_
23	attacks	_	VBZ	VBZ	_	22	SBAR	_	_
24	the	_	DT	DT	_	25	NMOD	_	_
25	virus	_	NN	NN	_	23	OBJ	_	_
26	in	_	IN	IN	_	23	VMOD	_	_
27	a	_	DT	DT	_	29	NMOD	_	_
28	different	_	JJ	JJ	_	29	NMOD	_	_
29	way	_	NN	NN	_	26	PMOD	_	_

1	a	_	DT	DT	_	2	NMOD	_	_
2	woman	_	NN	NN	_	3	SUB	_	_
3	wears	_	VBZ	VBZ	_	0	ROOT	_	_
4	an	_	DT	DT	_	7	NMOD	_	_
5	@	_	JJ	JJ	_	7	NMOD	_	_
6	entity10	_	CD	CD	_	7	NMOD	_	_
7	ribbon	_	NN	NN	_	3	OBJ	_	_
8	at	_	IN	IN	_	3	VMOD	_	_
9	a	_	DT	DT	_	11	NMOD	_	_
10	@	_	JJ	JJ	_	11	NMOD	_	_
11	entity12	_	NN	NN	_	16	NMOD	_	_
12	,	_	,	,	_	16	P	_	_
13	@	_	NN	NN	_	16	NMOD	_	_
14	entity13	_	CD	CD	_	13	NMOD	_	_
15	,	_	,	,	_	13	P	_	_
16	hospital	_	NN	NN	_	8	PMOD	_	_
17	where	_	WRB	WRB	_	16	NMOD	_	_
18	@	_	JJ	JJ	_	20	NMOD	_	_
19	entity5	_	CD	CD	_	20	NMOD	_	_
20	patients	_	NNS	NNS	_	21	SUB	_	_
21	are	_	VBP	VBP	_	17	SBAR	_	_
22	treated	_	VBN	VBN	_	21	VC	_	_

1	@	_	NNP	NNP	_	9	SUB	_	_
2	entity15	_	CD	CD	_	1	NMOD	_	_
3	,	_	,	,	_	1	P	_	_
4	developed	_	VBN	VBN	_	1	NMOD	_	_
5	by	_	IN	IN	_	4	VMOD	_	_
6	@	_	VBG	VBG	_	5	PMOD	_	_
7	entity16	_	CD	CD	_	6	OBJ	_	_
8	,	_	,	,	_	1	P	_	_
9	is	_	VBZ	VBZ	_	0	ROOT	_	_
10	designed	_	VBN	VBN	_	9	VC	_	_
11	for	_	IN	IN	_	10	VMOD	_	_
12	patients	_	NNS	NNS	_	11	PMOD	_	_
13	who	_	WP	WP	_	12	NMOD	_	_
14	have	_	VBP	VBP	_	13	SBAR	_	_
15	shown	_	VBN	VBN	_	14	VC	_	_
16	resistance	_	NN	NN	_	15	OBJ	_	_
17	to	_	TO	TO	_	15	VMOD	_	_
18	current	_	JJ	JJ	_	19	NMOD	_	_
19	treatments	_	NNS	NNS	_	17	PMOD	_	_

1	the	_	DT	DT	_	2	NMOD	_	_
2	drug	_	NN	NN	_	3	SUB	_	_
3	has	_	VBZ	VBZ	_	18	VMOD	_	_
4	been	_	VBN	VBN	_	3	VC	_	_
5	approved	_	VBN	VBN	_	4	VC	_	_
6	for	_	IN	IN	_	5	VMOD	_	_
7	adults	_	NNS	NNS	_	6	PMOD	_	_
8	who	_	WP	WP	_	7	NMOD	_	_
9	already	_	RB	RB	_	10	VMOD	_	_
10	have	_	VBP	VBP	_	8	SBAR	_	_
11	been	_	VBN	VBN	_	10	VC	_	_
12	receiving	_	VBG	VBG	_	11	VC	_	_
13	treatment	_	NN	NN	_	12	OBJ	_	_
14	,	_	,	,	_	18	P	_	_
15	but	_	CC	CC	_	18	VMOD	_	_
16	more	_	JJR	JJR	_	17	NMOD	_	_
17	testing	_	NN	NN	_	18	SUB	_	_
18	is	_	VBZ	VBZ	_	34	VMOD	_	_
19	necessary	_	JJ	JJ	_	18	PRD	_	_
20	before	_	IN	IN	_	18	VMOD	_	_
21	it	_	PRP	PRP	_	22	SUB	_	_
22	is	_	VBZ	VBZ	_	20	SBAR	_	_
23	approved	_	VBN	VBN	_	22	VC	_	_
24	for	_	IN	IN	_	23	VMOD	_	_
25	new	_	JJ	JJ	_	30	NMOD	_	_
26	@	_	JJ	JJ	_	30	NMOD	_	_
27	entity5	_	CD	CD	_	28	NMOD	_	_
28	patients	_	NNS	NNS	_	30	NMOD	_	_
29	or	_	CC	CC	_	30	NMOD	_	_
30	children	_	NNS	NNS	_	24	PMOD	_	_
31	,	_	,	,	_	34	P	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	company	_	NN	NN	_	34	SUB	_	_
34	said	_	VBD	VBD	_	0	ROOT	_	_
35	in	_	IN	IN	_	34	VMOD	_	_
36	a	_	DT	DT	_	37	NMOD	_	_
37	statement	_	NN	NN	_	35	PMOD	_	_

1	@	_	NNP	NNP	_	3	SUB	_	_
2	entity15	_	CD	CD	_	1	NMOD	_	_
3	belongs	_	VBZ	VBZ	_	0	ROOT	_	_
4	to	_	TO	TO	_	3	VMOD	_	_
5	a	_	DT	DT	_	6	NMOD	_	_
6	class	_	NN	NN	_	4	PMOD	_	_
7	of	_	IN	IN	_	6	NMOD	_	_
8	drugs	_	NNS	NNS	_	7	PMOD	_	_
9	called	_	VBN	VBN	_	6	NMOD	_	_
10	integrase	_	NN	NN	_	11	NMOD	_	_
11	inhibitors	_	NNS	NNS	_	9	VMOD	_	_

1	these	_	DT	DT	_	2	NMOD	_	_
2	drugs	_	NNS	NNS	_	3	SUB	_	_
3	work	_	VBP	VBP	_	0	ROOT	_	_
4	by	_	IN	IN	_	3	VMOD	_	_
5	blocking	_	VBG	VBG	_	4	PMOD	_	_
6	the	_	DT	DT	_	8	NMOD	_	_
7	integrase	_	NN	NN	_	8	NMOD	_	_
8	enzyme	_	NN	NN	_	5	OBJ	_	_
9	,	_	,	,	_	8	P	_	_
10	which	_	WDT	WDT	_	8	NMOD	_	_
11	helps	_	VBZ	VBZ	_	10	SBAR	_	_
12	@	_	NN	NN	_	14	NMOD	_	_
13	entity5	_	CD	CD	_	14	NMOD	_	_
14	replicate	_	NN	NN	_	11	OBJ	_	_
15	by	_	IN	IN	_	11	VMOD	_	_
16	inserting	_	VBG	VBG	_	15	PMOD	_	_
17	its	_	PRP$	PRP$	_	18	NMOD	_	_
18	dna	_	NN	NN	_	16	OBJ	_	_
19	into	_	IN	IN	_	16	VMOD	_	_
20	new	_	JJ	JJ	_	21	NMOD	_	_
21	cells	_	NNS	NNS	_	19	PMOD	_	_

1	@	_	NNP	NNP	_	3	SUB	_	_
2	entity15	_	CD	CD	_	1	NMOD	_	_
3	is	_	VBZ	VBZ	_	0	ROOT	_	_
4	the	_	DT	DT	_	6	NMOD	_	_
5	first	_	JJ	JJ	_	6	NMOD	_	_
6	drug	_	NN	NN	_	3	PRD	_	_
7	in	_	IN	IN	_	6	NMOD	_	_
8	the	_	DT	DT	_	9	NMOD	_	_
9	class	_	NN	NN	_	7	PMOD	_	_
10	to	_	TO	TO	_	11	VMOD	_	_
11	win	_	VB	VB	_	6	NMOD	_	_
12	@	_	NN	NN	_	14	NMOD	_	_
13	entity1	_	CD	CD	_	14	NMOD	_	_
14	approval	_	NN	NN	_	11	OBJ	_	_

1	dr	_	NN	NN	_	0	ROOT	_	_

1	@	_	NNP	NNP	_	10	NMOD	_	_
2	entity38	_	CD	CD	_	1	NMOD	_	_
3	,	_	,	,	_	10	P	_	_
4	a	_	DT	DT	_	10	NMOD	_	_
5	noted	_	VBN	VBN	_	10	NMOD	_	_
6	@	_	NN	NN	_	10	NMOD	_	_
7	entity5	_	CD	CD	_	10	NMOD	_	_
8	expert	_	NN	NN	_	10	NMOD	_	_
9	and	_	CC	CC	_	10	NMOD	_	_
10	director	_	NN	NN	_	20	SUB	_	_
11	of	_	IN	IN	_	10	NMOD	_	_
12	the	_	DT	DT	_	13	NMOD	_	_
13	@	_	NN	NN	_	11	PMOD	_	_
14	entity40	_	CD	CD	_	13	NMOD	_	_
15	at	_	IN	IN	_	10	NMOD	_	_
16	the	_	DT	DT	_	17	NMOD	_	_
17	@	_	NN	NN	_	15	PMOD	_	_
18	entity41	_	CD	CD	_	17	NMOD	_	_
19	,	_	,	,	_	10	P	_	_
20	said	_	VBD	VBD	_	0	ROOT	_	_
21	the	_	DT	DT	_	24	NMOD	_	_
22	@	_	NN	NN	_	24	NMOD	_	_
23	entity1	_	NN	NN	_	24	NMOD	_	_
24	's	_	POS	POS	_	25	NMOD	_	_
25	approval	_	NN	NN	_	27	SUB	_	_
26	``	_	``	``	_	27	P	_	_
27	will	_	MD	MD	_	20	VMOD	_	_
28	be	_	VB	VB	_	27	VC	_	_
29	most	_	RBS	RBS	_	30	AMOD	_	_
30	welcome	_	JJ	JJ	_	28	PRD	_	_
31	in	_	IN	IN	_	30	NMOD	_	_
32	the	_	DT	DT	_	33	NMOD	_	_
33	community	_	NN	NN	_	31	PMOD	_	_
34	of	_	IN	IN	_	33	NMOD	_	_
35	physicians	_	NNS	NNS	_	34	PMOD	_	_
36	taking	_	VBG	VBG	_	35	NMOD	_	_
37	care	_	NN	NN	_	43	NMOD	_	_
38	of	_	IN	IN	_	37	NMOD	_	_
39	@	_	NN	NN	_	38	PMOD	_	_
40	entity5	_	CD	CD	_	39	NMOD	_	_
41	-	_	:	:	_	43	P	_	_
42	infected	_	JJ	JJ	_	43	NMOD	_	_
43	patients	_	NNS	NNS	_	36	OBJ	_	_

1	``	_	``	``	_	31	P	_	_
2	``	_	``	``	_	31	P	_	_
3	its	_	PRP$	PRP$	_	4	NMOD	_	_
4	mechanism	_	NN	NN	_	7	SUB	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	action	_	NN	NN	_	5	PMOD	_	_
7	is	_	VBZ	VBZ	_	31	VMOD	_	_
8	particularly	_	RB	RB	_	9	AMOD	_	_
9	important	_	JJ	JJ	_	7	PRD	_	_
10	in	_	IN	IN	_	9	AMOD	_	_
11	that	_	IN	IN	_	9	AMOD	_	_
12	it	_	PRP	PRP	_	13	SUB	_	_
13	blocks	_	NNS	NNS	_	11	SBAR	_	_
14	the	_	DT	DT	_	15	NMOD	_	_
15	ability	_	NN	NN	_	13	OBJ	_	_
16	of	_	IN	IN	_	15	NMOD	_	_
17	the	_	DT	DT	_	18	NMOD	_	_
18	virus	_	NN	NN	_	16	PMOD	_	_
19	to	_	TO	TO	_	20	VMOD	_	_
20	integrate	_	VB	VB	_	15	NMOD	_	_
21	itself	_	PRP	PRP	_	20	OBJ	_	_
22	into	_	IN	IN	_	20	VMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	genes	_	NNS	NNS	_	22	PMOD	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	cells	_	NNS	NNS	_	25	PMOD	_	_
27	,	_	,	,	_	31	P	_	_
28	``	_	``	``	_	31	P	_	_
29	@	_	NN	NN	_	31	SUB	_	_
30	entity38	_	CD	CD	_	29	NMOD	_	_
31	said	_	VBD	VBD	_	0	ROOT	_	_

1	``	_	``	``	_	9	P	_	_
2	this	_	DT	DT	_	3	NMOD	_	_
3	property	_	NN	NN	_	9	SUB	_	_
4	of	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	6	NMOD	_	_
6	virus	_	NN	NN	_	4	PMOD	_	_
7	to	_	TO	TO	_	8	VMOD	_	_
8	integrate	_	VB	VB	_	6	NMOD	_	_
9	is	_	VBZ	VBZ	_	0	ROOT	_	_
10	important	_	JJ	JJ	_	9	PRD	_	_
11	in	_	IN	IN	_	10	AMOD	_	_
12	establishing	_	VBG	VBG	_	11	PMOD	_	_
13	the	_	DT	DT	_	14	NMOD	_	_
14	reservoir	_	NN	NN	_	12	OBJ	_	_
15	of	_	IN	IN	_	14	NMOD	_	_
16	virus	_	NN	NN	_	15	PMOD	_	_
17	in	_	IN	IN	_	12	VMOD	_	_
18	the	_	DT	DT	_	19	NMOD	_	_
19	body	_	NN	NN	_	17	PMOD	_	_
20	that	_	WDT	WDT	_	19	NMOD	_	_
21	has	_	VBZ	VBZ	_	20	SBAR	_	_
22	made	_	VBN	VBN	_	21	VC	_	_
23	it	_	PRP	PRP	_	27	SUB	_	_
24	extremely	_	RB	RB	_	25	AMOD	_	_
25	difficult	_	JJ	JJ	_	27	PRD	_	_
26	to	_	TO	TO	_	27	VMOD	_	_
27	eradicate	_	VB	VB	_	22	VMOD	_	_
28	@	_	NN	NN	_	27	OBJ	_	_
29	entity5	_	CD	CD	_	28	NMOD	_	_
30	,	_	,	,	_	27	P	_	_
31	even	_	RB	RB	_	32	PMOD	_	_
32	with	_	IN	IN	_	27	VMOD	_	_
33	prolonged	_	JJ	JJ	_	34	NMOD	_	_
34	treatment	_	NN	NN	_	32	PMOD	_	_

1	``	_	``	``	_	17	P	_	_
2	two	_	CD	CD	_	4	NMOD	_	_
3	earlier	_	JJR	JJR	_	4	NMOD	_	_
4	classes	_	NNS	NNS	_	17	SUB	_	_
5	of	_	IN	IN	_	4	NMOD	_	_
6	@	_	JJ	JJ	_	8	NMOD	_	_
7	entity64	_	CD	CD	_	8	NMOD	_	_
8	drugs	_	NNS	NNS	_	14	NMOD	_	_
9	--	_	:	:	_	14	P	_	_
10	protease	_	NN	NN	_	14	NMOD	_	_
11	and	_	CC	CC	_	14	NMOD	_	_
12	reverse	_	VB	VB	_	14	NMOD	_	_
13	transcriptase	_	JJ	JJ	_	14	NMOD	_	_
14	inhibitors	_	NNS	NNS	_	5	PMOD	_	_
15	--	_	:	:	_	14	P	_	_
16	also	_	RB	RB	_	17	VMOD	_	_
17	work	_	VBP	VBP	_	0	ROOT	_	_
18	by	_	IN	IN	_	17	VMOD	_	_
19	blocking	_	VBG	VBG	_	18	PMOD	_	_
20	different	_	JJ	JJ	_	21	NMOD	_	_
21	enzymes	_	NNS	NNS	_	19	OBJ	_	_
22	involved	_	VBN	VBN	_	21	NMOD	_	_
23	in	_	IN	IN	_	22	VMOD	_	_
24	@	_	JJ	JJ	_	26	NMOD	_	_
25	entity5	_	CD	CD	_	26	NMOD	_	_
26	replication	_	NN	NN	_	23	PMOD	_	_

1	friday	_	NNP	NNP	_	2	NMOD	_	_
2	's	_	POS	POS	_	3	NMOD	_	_
3	decision	_	NN	NN	_	8	SUB	_	_
4	by	_	IN	IN	_	3	NMOD	_	_
5	the	_	DT	DT	_	7	NMOD	_	_
6	@	_	NN	NN	_	7	NMOD	_	_
7	entity1	_	NN	NN	_	4	PMOD	_	_
8	will	_	MD	MD	_	0	ROOT	_	_
9	give	_	VB	VB	_	8	VC	_	_
10	doctors	_	NNS	NNS	_	9	OBJ	_	_
11	a	_	DT	DT	_	13	NMOD	_	_
12	new	_	JJ	JJ	_	13	NMOD	_	_
13	tool	_	NN	NN	_	9	OBJ	_	_
14	to	_	TO	TO	_	15	VMOD	_	_
15	help	_	VB	VB	_	13	NMOD	_	_
16	patients	_	NNS	NNS	_	15	OBJ	_	_
17	who	_	WP	WP	_	25	DEP	_	_
18	have	_	VBP	VBP	_	17	SBAR	_	_
19	developed	_	VBN	VBN	_	18	VC	_	_
20	resistance	_	NN	NN	_	19	OBJ	_	_
21	to	_	TO	TO	_	20	NMOD	_	_
22	existing	_	VBG	VBG	_	23	NMOD	_	_
23	drugs	_	NNS	NNS	_	21	PMOD	_	_
24	or	_	CC	CC	_	25	DEP	_	_
25	who	_	WP	WP	_	16	NMOD	_	_
26	are	_	VBP	VBP	_	25	SBAR	_	_
27	infected	_	VBN	VBN	_	26	VC	_	_
28	with	_	IN	IN	_	27	VMOD	_	_
29	drug	_	NN	NN	_	32	NMOD	_	_
30	-	_	:	:	_	32	P	_	_
31	resistant	_	JJ	JJ	_	32	NMOD	_	_
32	strains	_	NNS	NNS	_	28	PMOD	_	_
33	of	_	IN	IN	_	32	NMOD	_	_
34	@	_	NN	NN	_	33	PMOD	_	_
35	entity5	_	CD	CD	_	34	NMOD	_	_

1	like	_	IN	IN	_	10	VMOD	_	_
2	protease	_	NN	NN	_	1	PMOD	_	_
3	and	_	CC	CC	_	2	VMOD	_	_
4	reverse	_	VB	VB	_	2	VMOD	_	_
5	transcriptase	_	JJ	JJ	_	6	NMOD	_	_
6	inhibitors	_	NNS	NNS	_	4	OBJ	_	_
7	,	_	,	,	_	10	P	_	_
8	@	_	NN	NN	_	9	NMOD	_	_
9	entity15	_	NN	NN	_	10	SUB	_	_
10	will	_	MD	MD	_	29	VMOD	_	_
11	also	_	RB	RB	_	10	VMOD	_	_
12	be	_	VB	VB	_	10	VC	_	_
13	prescribed	_	VBN	VBN	_	12	VC	_	_
14	for	_	IN	IN	_	13	VMOD	_	_
15	patients	_	NNS	NNS	_	14	PMOD	_	_
16	in	_	IN	IN	_	15	NMOD	_	_
17	combination	_	NN	NN	_	16	PMOD	_	_
18	with	_	IN	IN	_	17	NMOD	_	_
19	other	_	JJ	JJ	_	20	NMOD	_	_
20	drugs	_	NNS	NNS	_	18	PMOD	_	_
21	to	_	TO	TO	_	22	VMOD	_	_
22	maximize	_	VB	VB	_	20	NMOD	_	_
23	the	_	DT	DT	_	24	NMOD	_	_
24	number	_	NN	NN	_	22	OBJ	_	_
25	of	_	IN	IN	_	24	NMOD	_	_
26	ways	_	NNS	NNS	_	25	PMOD	_	_
27	the	_	DT	DT	_	28	NMOD	_	_
28	virus	_	NN	NN	_	29	SUB	_	_
29	is	_	VBZ	VBZ	_	0	ROOT	_	_
30	being	_	VBG	VBG	_	29	VC	_	_
31	attacked	_	VBN	VBN	_	30	VC	_	_

1	the	_	DT	DT	_	2	NMOD	_	_
2	cost	_	NN	NN	_	15	NMOD	_	_
3	of	_	IN	IN	_	2	NMOD	_	_
4	the	_	DT	DT	_	7	NMOD	_	_
5	recommended	_	JJ	JJ	_	7	NMOD	_	_
6	daily	_	JJ	JJ	_	7	NMOD	_	_
7	regimen	_	NN	NN	_	3	PMOD	_	_
8	of	_	IN	IN	_	7	NMOD	_	_
9	@	_	NN	NN	_	8	PMOD	_	_
10	entity15	_	CD	CD	_	9	NMOD	_	_
11	--	_	:	:	_	15	P	_	_
12	a	_	DT	DT	_	15	NMOD	_	_
13	400	_	CD	CD	_	15	NMOD	_	_
14	mg	_	NN	NN	_	15	NMOD	_	_
15	tablet	_	NN	NN	_	21	SUB	_	_
16	taken	_	VBN	VBN	_	15	NMOD	_	_
17	twice	_	RB	RB	_	19	NMOD	_	_
18	a	_	DT	DT	_	19	NMOD	_	_
19	day	_	NN	NN	_	16	OBJ	_	_
20	--	_	:	:	_	15	P	_	_
21	will	_	MD	MD	_	38	VMOD	_	_
22	be	_	VB	VB	_	21	VC	_	_
23	comparable	_	JJ	JJ	_	22	PRD	_	_
24	to	_	TO	TO	_	25	VMOD	_	_
25	protease	_	VB	VB	_	23	AMOD	_	_
26	inhibitors	_	NNS	NNS	_	25	OBJ	_	_
27	,	_	,	,	_	25	P	_	_
28	with	_	IN	IN	_	25	VMOD	_	_
29	a	_	DT	DT	_	31	NMOD	_	_
30	wholesale	_	JJ	JJ	_	31	NMOD	_	_
31	price	_	NN	NN	_	28	PMOD	_	_
32	of	_	IN	IN	_	31	NMOD	_	_
33	$	_	$	$	_	34	P	_	_
34	27	_	CD	CD	_	32	PMOD	_	_
35	,	_	,	,	_	38	P	_	_
36	@	_	RB	RB	_	38	VMOD	_	_
37	entity16	_	CD	CD	_	36	AMOD	_	_
38	said	_	VBD	VBD	_	0	ROOT	_	_

1	e-mail	_	NN	NN	_	2	SUB	_	_
2	to	_	TO	TO	_	0	ROOT	_	_
3	a	_	DT	DT	_	4	NMOD	_	_
4	friend	_	NN	NN	_	2	PMOD	_	_

1	more	_	RBR	RBR	_	2	AMOD	_	_
2	testing	_	VBG	VBG	_	14	VMOD	_	_
3	necessary	_	JJ	JJ	_	2	PRD	_	_
4	before	_	IN	IN	_	2	VMOD	_	_
5	it	_	PRP	PRP	_	6	SUB	_	_
6	is	_	VBZ	VBZ	_	4	SBAR	_	_
7	approved	_	VBN	VBN	_	6	VC	_	_
8	for	_	IN	IN	_	7	VMOD	_	_
9	new	_	JJ	JJ	_	12	NMOD	_	_
10	@	_	JJ	JJ	_	12	NMOD	_	_
11	placeholder	_	NN	NN	_	12	NMOD	_	_
12	patients	_	NNS	NNS	_	8	PMOD	_	_
13	,	_	,	,	_	14	P	_	_
14	children	_	NNS	NNS	_	0	ROOT	_	_

